FORM	4
------	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)											
1. Name and Address of Reporting Person- Kelly Paul Edward	2. Issuer Name and Ticker or Trading Symbol RELMADA THERAPEUTICS, INC. [RLMD]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) C/O RELMADA THERAPEUTICS THIRD AVENUE, 12TH FLOOR	3. Date of Earliest Transaction (Month/Day/Year) 02/24/2021						Officer (give title below)Oth	her (specify belo	w)		
(Street) NEW YORK, NY 10022	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State)	(Zip)		Table I - N	Non-E	Derivative	Secur	ities Acqui	red, Disposed of, or Beneficially Own	vned		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye		2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Owned Following Reported Transaction(s)	Ownership Form:	Beneficial	
		(Month/Day/Year)	Code	Code V		(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	02/24/2021		М		5,000	А	\$ 3.24	172,295	D		
Common Stock	02/24/2021		S ⁽¹⁾		2,429 (<u>2</u>)	D	\$ 33.6661 (<u>3</u>)	169,866	D		
Common Stock	02/24/2021		S ⁽¹⁾		2,463 (2)	D	\$ 34.6387 (<u>4</u>)	167,403	D		
Common Stock	02/24/2021		S ⁽¹⁾		108 (2)	D	\$ 35.5826 (5)	167,295	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts calls warrants options convertible securities)

1. Title of Derivative Scurity Security 3. Transaction Date Conversion of Execution Date in any (Instr. 3) 3. Loemed Execution Date, if Code (Instr. 8) and (Instr. 4) 5. Number of Code (Instr. 8) and (Instr. 4) 7. Title and Amount of Indirect Scurity (Instr. 3) 8. Price of Derivative Scurity (Instr. 3) 9. Number of Derivative Scurity (Instr. 3) 9. Number of Indirect Scurity (Instr. 3) 10. Derivative Scurity Scurity (Instr. 4) 9. Number of Indirect Scurity Scurity (Instr. 4) 10. Muth/Day/Year) 10. Title and Mount (Instr. 4) 8. Price of Derivative Scurity (Instr. 4) 9. Number of Indirect Scurity (Instr. 4) 9. Number of Indirect Scurity (Instr. 4) 10. Muth/Day/Year) 10. Muth/Day/Ye		(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)														
Security (Instr. 3) or Exercise Price of Derivative Security (Month/Day/Year) any (Month/Day/Year) Code (Instr. 8) Derivative (Instr. 8) Securities (Instr. 3 and 4) Securities (Instr. 3 and 4) Securities (Instr. 3 and 4) Securities Beneficially Owned Forward (Instr. 4) Form of Derivative Security Beneficial Ownership (Instr. 4) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1. Title of	2.	3. Transaction	3A. Deemed	4.		5. N	umber	6. Date Exercisab	le and	7. Title and	Amount	8. Price of	9. Number of	10.	11. Nature
(Instr. 3) Price of Derivative Security (Month/Day/Year) (Instr. 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) (Instr. 3) Instr. 5) Beneficially Owned Following Reported (Instr. 4) Derivative Security: (Instr. 4) Owneship (Instr. 4) Options to purchase common \$ 3.24 02/08/2021 M M 5,000 10/20/2017 ⁽⁶⁾ 10/20/2027 Common Stock 5,000 \$ 0 ⁽⁷⁾ 55,500 D	Derivative	Conversion	Date	Execution Date, if	Transact	ion	of		Expiration Date		of Underlyin	ng	Derivative	Derivative	Ownership	of Indirect
$ \begin{array}{ c c c c c c } \hline \begin{tabular}{ c c c c } \hline \begin{tabular}{ c c c c } \hline \begin{tabular}{ c c c c c } \hline \begin{tabular}{ c c c c c c c } \hline \begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Security	or Exercise	(Month/Day/Year)	any	Code		Deri	vative	(Month/Day/Year	r)	Securities		Security	Securities	Form of	Beneficial
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Secu	irities			(Instr. 3 and	4)	(Instr. 5)	Beneficially	Derivative	Ownership
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Derivative					Acq	uired						Owned	Security:	(Instr. 4)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Security					(A)	or						Following	Direct (D)	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$							Disp	osed						Reported	or Indirect	
$\begin{array}{ c c c c c c c c }\hline \hline \\ \hline$							of (I	D)						Transaction(s)	(I)	
Options to purchase\$ 3.2402/08/2021MMISource shareSource shareIntelAmount or SharesAmount or SharesAmount or SharesAmount or SharesIntelAmount or SharesAmount or SharesIntelIntelAmount or SharesIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntelIntel														(Instr. 4)	(Instr. 4)	
Options to purchase\$3.2402/08/2021O2/08/2021MIIIIIDate ExercisableExpiration DateTitleOr Number of DateIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>and</td> <td>5)</td> <td colspan="2"></td> <td colspan="2"></td> <td></td> <td></td> <td></td> <td></td>							and	5)								
Options to purchase\$3.2402/08/2021O2/08/2021MIIIIIDate ExercisableExpiration DateTitleOr Number of DateIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII </td <td></td> <td>Amount</td> <td></td> <td></td> <td></td> <td></td>												Amount				
Options to purchase common \$ 3.24 02/08/2021 M K 5,000 10/20/2017 ⁽⁶⁾ 10/20/2027 Common Stock 5,000 \$ 0 ⁽⁷⁾ 55,500 D									D .	n						
Options to purchase common\$3.2402/08/2021OcdeV(A)(D)Options (D)10/20/2017Common StockS,000\$ 0 (7)55,500D										-	Title	Number				
Options to purchase common \$ 3.24 02/08/2021 M 5,000 10/20/2017 ⁽⁶⁾ 10/20/2027 Common Stock 5,000 \$ 0 ⁽⁷⁾ 55,500 D									Exercisable	Date		of				
to purchase common \$ 3.24 02/08/2021 M 5,000 10/20/2017 ⁽⁶⁾ 10/20/2027 Common Stock 5,000 \$ 0 ⁽⁷⁾ 55,500 D					Code	V	(A)	(D)				Shares				
to purchase common \$ 3.24 02/08/2021 M 5,000 10/20/2017 ⁽⁶⁾ 10/20/2027 Common Stock 5,000 \$ 0 ⁽⁷⁾ 55,500 D	Options															
purchase common \$ 3.24 02/08/2021 M 5,000 10/20/2017 ⁽⁶⁾ 10/20/2027 Common Stock 5,000 \$ 0 ⁽⁷⁾ 55,500 D	-															
common Stock		\$ 2 24	02/08/2021		м			5 000	10/20/2017(6)	10/20/2027	Common	5 000	¢ o (7)	55 500	D	
common	purchase	\$ 3.24	02/08/2021		IVI			5,000	10/20/2017	10/20/2027	Stock	5,000	\$ 0	55,500	D	
stock	common										21001					
	stock															

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Kelly Paul Edward C/O RELMADA THERAPEUTICS, INC. 880 THIRD AVENUE, 12TH FLOOR NEW YORK, NY 10022	Х						

Signatures

/s/ Paul E. Kelly	02/26/2021
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.
- The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted (2) average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- (3) Sales prices range from \$33.29 to \$34.28 per share, inclusive.
- (4) Sales prices range from \$34.29 to \$35.15 per share, inclusive.
- (5) Sales prices range from \$35.49 to \$35.59 per share, inclusive.
- (6) The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

(7) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.